Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So I'm encouraged that we will see a lot of volume here going forward on this |
| In the fourth quarter, we delivered higher-than-expected consolidated revenue of approximately $1.12 billion |
| We also will benefit from some uptick in terms of all the actions we have taken to improve COGS productivity |
| I'm excited to be part of Illumina's leadership team that is driving our unmatched core business forward |
| So we're quite encouraged about that |
| These conversations are informing my leadership agenda and importantly have reinforced my confidence in Illumina's core business |
| So I think if you dig into the details, you will actually realize that Illumina has a very attractive and very differentiated platform |
| As you aware, XLEAP-SBS chemistry has been the engine for our X platform, delivering significant improvements in quality, turnaround time and cost |
| Despite these impacts Core Illumina revenue exceeded expectations due to stronger than projected NovaSeq X placements and uptake in X consumables with strong early demand for the 25B flow cell that launched in Q4 |
| This offering will further strengthen our leadership position around the world and drive progress in markets such as single cell, spatial and proteomics |
| Joydeep Goswami I'd just add, Jacob, that we are about the only company that has -- even in our REO products, ISO 13485 classification on all our instruments and most of our consumables, and we have, obviously, the path to IBD should our customers want it, right? So we're well positioned to serve whichever direction they want to go in |
| So, let me start by saying we were very encouraged by the uptake of the 25B and 10B flow cells that we saw in the fourth quarter |
| Core Illumina sequencing service and other revenue of $152 million was up 16% year-over-year, driven primarily by an increase in revenue from strategic partnerships and higher instrument service contract revenue on a growing installed base |
| We're also very pleased to see the elasticity, the growth in underlying sequencing activity being driven by ex-customers, right? So both of those are good |
| But what I can tell you is that I think Illumina is very well positioned to support the markets going forward, almost independent on where FDA is landing on this one |
| In turn, this will help capitalize our market-leading innovation and continue to differentiate Illumina and maintain our industry-leading position across research and clinical markets |
| But as I mentioned, you know, we are very pleased with the announcement that we made here in December that we are now divesting GRAIL for sure and I'm actually very pleased with the progress so far |
| Non-GAAP EPS exceeded our expectations, driven by higher revenue and gross margin and lower operating expense for the quarter |
| And of course, if the if the markets pick up, we are very well positioned then to benefit from any of the upside |
| This will build momentum for consumables demand this year and going forward |
| Our operating margin expectations reflect the benefit of our continued gross margin improvement and expense reduction initiatives, offset by normalization of our performance-based compensation, as well as the impacts from inflation and market-based merit increases |
| While we will continue to see customers reduce their inventories of NovaSeq 6000 consumables as they transition to the X building pull-through on the NovaSeq X will drive our overall high-throughput consumables growth this year |
| So I feel really good about that |
| Illumina has the opportunity to truly drive the next-generation sequencing ecosystem forward |
| So I think we feel that we have a very attractive solution |
| We -- as I said, one of the things -- what I said previously, is one of the things that I was really excited about is the pipeline of innovation that we have in running right now and thereby, also there will be a lot of innovation coming out from Illumina over the next period of time here |
| In Q4, we saw higher-than-expected growth in X consumables sales following the late October, launch of our much anticipated 25B reagent kit |
| So those are the two largest things that will serve to improve our gross margins as we get to '24 |
| So let me start by saying that we've been very pleased with the pickup of the 25B since the launch in late November |
| Europe revenue was up 17% year-on-year on a relatively easy prior year comparable |
| Statement |
|---|
| Greater China revenue was down 13% year-over-year, reflecting continued geopolitical challenges and local competition and mid-throughput |
| On the flip side, it's further macroeconomic headwinds that further reduce our customers' ability to bring on the X or to spend on consumables will affect us as well |
| We expect Core Illumina sequencing instrument revenue to decline in the high-teens year-over-year, driven primarily by a decrease in NovaSeq X instrument placements |
| Amid a challenging macroeconomic backdrop that we saw many of our customers remaining constrained in their purchasing decisions |
| Core Illumina non-GAAP gross margin of 64.7% for the quarter decreased 260 basis points year-over-year, primarily driven by the mix of lower-margin strategic partnership revenue, lower instrument margins due to the NovaSeq X launch, which is typical with a new platform introduction and increased field services and installation costs, partially offset by lower freight costs |
| Non-GAAP operating loss of $152 million for the quarter |
| So Patrick, in terms of sequential decrease in fourth quarter on gross margin, there are several factors there, right? One, revenue was lower |
| When will that be made public? And the reason I ask is, GRAIL's operating losses were $700 million last year |
| EMEA revenue declined 1%, although that included a 10 percentage point impact from sanctions in Russia |
| As Jacob mentioned, our outlook assumes the current challenging macroeconomic environment persist in 2024 and tighter funding and budget pressures continue to impact our customers' purchasing decisions |
| Globally, we expect our customers will remain cautious |
| For the first quarter of 2024, we expect Core Illumina revenue in the range of $1.03 million to $1.04 billion, reflecting a Year-over-Year decrease of 3.5% to 4.5%, driven predominantly by the following factors |
| We expect lower NovaSeq X instrument shipments year-over-year given that we are entering 2024 with a more modest backlog, compared to the significant pre-order book |
| Total sequencing consumables revenue was also impacted by COVID, Russia and China factors that I previously noted, as well as the continued impact of macroeconomic conditions on customer's purchasing behavior |
| The impact of our effective tax rate in 2023 was more significant due to our lower earnings |
| You mentioned that the gross margin line in 4Q was lighter due to that consumables mix shift from 6000 to X |
| So it seems like you probably had the opportunity to kind of establish an outlook that was softer than what you said in November |
| Growth in high-throughput instruments was partially offset by the expected decline in mid and low throughput shipments due to capital purchase and cash-flow constraints that continue to impact our customers' purchasing behaviors, as well as local competition in China |
| We also expect capital and cash flow constraints to continue to impact purchasing behavior and moderate instrument placements in 2024 |
| And then, of course, some of the expected again, reduction in NovaSeq 6000 consumables as customers switch from one platform to the other, right? So those -- that is the really big piece on the -- what's leading to the lower or the low-single-digit growth rate in consumables in 2024 |
Please consider a small donation if you think this website provides you with relevant information